Acute coronary syndrome
Conditions
Interventions
control group:None
Sponsors
The Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. In accordance with the guidelines for definite diagnosis of ACS and in patients undergoing PCI treatment: patients with acute myocardial infarction (including st-elevation myocardial infarction and non ST segment elevation myocardial infarction) diagnostic criteria: typical chest pain lasts more than 30 min, a typical dynamic electrocardiogram (ecg) changes or myocardial enzyme (creatine kinase isozyme or troponin) dynamic evolution;The diagnosis criteria of unstable angina(UA) is that history(risk factors for coronary heart disease), symptoms(initial or aggravation angina pectoris in 1 month), and ECG showing that ST-segment depresses or T wave changes. 2. Onset time =2 weeks; 3. Age range of included patients: 18-100 years old; 4. The subjects are willing to comply with the trial protocol, can understand the purpose of the trial, voluntarily participate in the trial or their legal guardian and sign the informed consent form, aged =18 years; 5. Complete clinical data and real follow-up data.
Exclusion criteria
Exclusion criteria: 1. Incomplete clinical data or (and) questionable authenticity of follow-up data; 2. Patients with dilated cardiomyopathy, hypertrophic cardiomyopathy, severe cardiogenic shock, history of active endocarditis, rheumatic heart disease, or severe valvular disease, severe liver and renal dysfunction, Severe hemorrhagic diseases, severe infectious diseases, severe respiratory diseases, hematological diseases, autoimmune diseases and craniocerebral diseases, malignant tumors, pulmonary embolism, ventricular septal perforation and aortic dissection; 3. Subjects who are considered by the investigator to have a serious medical condition that is not suitable for participation in the trial, or who have a life expectancy of less than 12 months; 4. Participating in other clinical trials, not yet out of the group or less than 3 months out of the group; 5. Known hypersensitivity to contrast media; 6. Subjects with contraindications of antiplatelet preparations and unable to receive antithrombotic therapy; 7. The researchers judged that the patients had poor treatment compliance and could not take the drugs for secondary prevention of coronary heart disease regularly as required.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiovascular Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| No reflow and atrial fibrillation after PCI, all-cause death other than cardiovascular death, stroke/cerebrovascular accident.; | — |
Countries
China
Contacts
Public ContactLi Wei
The Affiliated Hospital of Guizhou Medical University
Outcome results
None listed